Understanding the rhesus factor, commonly referred to as the Rh factor, is essential for anyone interested in human biology, pregnancy, or blood transfusions. This inherited protein, which can be present or absent on the surface of red blood cells, dictates whether your blood type is Rh positive or Rh negative. While the ABO system classifies blood based on specific antigens, the Rh factor adds another critical layer that determines compatibility and health risks. For the majority of the population, the Rh factor poses no daily concern, but its significance becomes undeniable during medical procedures, pregnancy, and emergency situations.
What is the Rh Factor?
The Rh factor is a specific protein found on the surface of red blood cells. If this protein is present, an individual is classified as Rh positive, which represents approximately 85% of the global population. Conversely, if the protein is absent, the person is Rh negative, making up the remaining 15%. The term "rhesus" originates from the Rhesus macaque monkey, in which the antigen was first identified in the 1940s. This antigen is independent of the ABO blood group system, meaning an individual can be type A positive, type B negative, or any other combination.
Genetics and Inheritance
The Rh factor is determined by genetics, following a dominant-recessive pattern. The gene responsible is located on chromosome 1, and an individual inherits one copy from each parent. If at least one copy of the dominant Rh-positive gene is present, the person will be Rh positive. Only if an individual inherits two recessive Rh-negative genes will they be Rh negative. This inheritance pattern means that two Rh-negative parents can only have an Rh-negative child, while an Rh-positive parent can pass on either trait, making the outcome variable in mixed pairings.
Clinical Significance in Pregnancy
Rh Incompatibility
The most critical medical concern regarding the Rh factor arises during pregnancy. If an Rh-negative woman carries an Rh-positive baby, her immune system may recognize the baby's blood cells as foreign. This usually occurs when fetal blood mixes with the maternal blood, such as during delivery or certain prenatal procedures. In response, the mother's body can produce anti-D antibodies, a process called sensitization. During a subsequent pregnancy with another Rh-positive baby, these antibodies can cross the placenta and attack the fetus's red blood cells, leading to Hemolytic Disease of the Fetus and Newborn (HDFN).
Prevention and Treatment
Fortunately, modern medicine has effectively mitigated the risks associated with Rh incompatibility. Rh-negative women are routinely screened early in pregnancy. If they are found to be unsensitized, they receive an injection of Rh immunoglobulin (RhIg), commonly known as Rho(D) immune globulin, around the 28th week of gestation and again within 72 hours after delivery. This injection works by "mopping up" any stray fetal Rh-positive blood cells before the mother's immune system can recognize and attack them, preventing the formation of harmful antibodies.
Blood Transfusions and Medical Procedures
Beyond pregnancy, the Rh factor is a vital consideration in blood transfusions. Transfusing Rh-positive blood into an Rh-negative patient can trigger an immune reaction, as the body will attack the newly introduced cells. Generally, Rh-negative patients should receive Rh-negative blood to ensure compatibility. However, in emergency situations where O-negative blood is scarce, Rh-positive blood may be transfused to Rh-negative females of childbearing age if it is life-saving, as the risk of severe reaction is weighed against the immediate need to stop hemorrhage.
